Condition: Head and Neck Cancer · Oral Cancer · Sponsor: Chang Gung Memorial Hospital
The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment. If this trial is successful, it is expected that it may be able to provide a standard diagnostic tool (MRD in Oral Cavity Squamous Cell Carcinoma (OCSCC)) and treatment mode (extended adjuvant chemotherapy with low-dose oral chemotherapy). The survival rate of patients will be improved.
This description comes directly from the study's public registry record.
ChunTa Liao, PhD · 0975360141 · liaoct@cgmh.org.tw
Chia-Hsun Hsieh, PhD · 0975366137 · wisdom5000@cgmh.org.tw
Always discuss trial participation with your own doctor first.
| Linkou Chang Gung Memorial Hospital | Taoyuan City, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07296250